Data analysis from the BEL-SPAIN Registry highlights real-world efficacy and safety in clinical practice.
Effects demonstrate potential for increased GC-sparing outcomes and treat-to-target strategies in therapy.
Abstract
BEL-based triple therapy is effective and safe in proliferative LN, achieving high renal and extrarenal response rates, substantial GC-sparing and treat-to-target outcomes in real-world practice.